Avax Technologies, Inc. Announces Completion of Bridge Loan

Exhibit 99.1


AVAX Technologies, Inc.


Contact:

OTCMarket: AVXT.OB


Richard Rainey

For Immediate Release


President


(913) 693-8491


AVAX Technologies, Inc. Announces Completion of Bridge Loan

- 5% $925,000 bridge loan matures may 17, 2004 -


Overland Park, KS, December 4, 2003 AVAX TECHNOLOGIES, INC. (OTCMarket: AVXT.OB) announces that it has closed a bridge financing in the aggregate principal amount of $925,000. The bridge notes mature on May 17, 2004 and bear interest at the rate of 5% per annum. In addition, the investors were granted warrants to purchase an aggregate of 7,115,300 shares of common stock at an exercise price of $0.143/share.


Richard Rainey, President of AVAX stated, "With the finalization of this loan facility we will continue the internal restructuring of our operations. Most recently, we have consolidated our manufacturing capabilities in Lyon, France where we will be able to ship world-wide the re-developed product format of our AC Vaccine therapeutic. This will allow us to continue our clinical and commercial programs with the AC Vaccine while also helping to finalize additional near term revenue opportunities through the offering of contract manufacturing services."


AVAX intends to use the proceeds principally to continue the clinical and commercial development of its AC Vaccine therapeutic, to maintain its current operations and to market its services for contract manufacturing. Significantly, the Company intends to capitalize on the following specific clinical development activities:


? In consultation with AFSSAPS (the French regulatory authorities), the filing of a BLA (biologics license application) in France for the treatment of melanoma patients;

? The treatment of melanoma patients in Europe on a "compassionate use" basis providing future product revenues;

? The filing of a Phase I/II IND (investigational new drug application) in France with AFSSAPS for the treatment of solid tumor cancer patients with metastases to the liver with the AC Vaccine;

? The amendment of an already approved U.S. IND for Ovaria ...